Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone339-970-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$223.33 million
Profitability
Miscellaneous
Employees715
OptionableOptionable
TESARO (NASDAQ:TSRO) Frequently Asked Questions
What is TESARO's stock symbol?
TESARO trades on the NASDAQ under the ticker symbol "TSRO."
How were TESARO's earnings last quarter?
TESARO Inc (NASDAQ:TSRO) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing analysts' consensus estimates of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to the consensus estimate of $65.50 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. The firm's quarterly revenue was up 94.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.82) earnings per share. View TESARO's Earnings History.
When is TESARO's next earnings date?
What price target have analysts set for TSRO?
22 analysts have issued twelve-month price targets for TESARO's stock. Their forecasts range from $25.00 to $146.00. On average, they anticipate TESARO's share price to reach $78.8571 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for TESARO.
What is the consensus analysts' recommendation for TESARO?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 16 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TESARO.
What are Wall Street analysts saying about TESARO stock?
Here are some recent quotes from research analysts about TESARO stock:
- 1. Cantor Fitzgerald analysts commented, ": 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies." (11/19/2018)
- 2. According to Zacks Investment Research, "TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2018)
Has TESARO been receiving favorable news coverage?
Press coverage about TSRO stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TESARO earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of TESARO's key competitors?
Some companies that are related to TESARO include Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO) and Marina Biotech (MRNA).
Who are TESARO's key executives?
TESARO's management team includes the folowing people:
- Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)
- Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)
- Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)
- Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)
- Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43)
Who are TESARO's major shareholders?
TESARO's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.00%), Alpine Associates Management Inc. (1.40%), Gardner Lewis Asset Management L P (1.33%), Frontier Capital Management Co. LLC (0.82%), Glazer Capital LLC (0.76%) and Macquarie Group Ltd. (0.54%). Company insiders that own TESARO stock include Arnold L Oronsky, David M Mott, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Joseph L Farmer, Lawrence M Alleva, Leon O Moulder Jr, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira, Peter J Barris and Timothy R Pearson. View Institutional Ownership Trends for TESARO.
Which institutional investors are selling TESARO stock?
TSRO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Interwest Venture Management Co., BlackRock Inc., Candriam Luxembourg S.C.A., Elk Creek Partners LLC, Bank of New York Mellon Corp, State of New Jersey Common Pension Fund D and Squarepoint Ops LLC. Company insiders that have sold TESARO company stock in the last year include Arnold L Oronsky, Grant C Bogle, Joseph L Farmer, Lawrence M Alleva, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira and Timothy R Pearson. View Insider Buying and Selling for TESARO.
Which institutional investors are buying TESARO stock?
TSRO stock was purchased by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Gardner Lewis Asset Management L P, Glazer Capital LLC, MUFG Securities EMEA plc, GABELLI & Co INVESTMENT ADVISERS INC., FNY Investment Advisers LLC, Manikay Partners LLC and P Schoenfeld Asset Management LP. Company insiders that have bought TESARO stock in the last two years include David M Mott, Enterprise Associates 13 L New, Leon O Moulder Jr and Peter J Barris. View Insider Buying and Selling for TESARO.
How do I buy shares of TESARO?
Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TESARO's stock price today?
One share of TSRO stock can currently be purchased for approximately $74.96.
How big of a company is TESARO?
TESARO has a market capitalization of $4.13 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. TESARO employs 715 workers across the globe.
What is TESARO's official website?
How can I contact TESARO?
TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.
MarketBeat Community Rating for TESARO (NASDAQ TSRO)
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
